These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1472 related items for PubMed ID: 27772640

  • 1. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M, Komenda P, Weinhandl ED, McCullough PA, Morfin JA.
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [Abstract] [Full Text] [Related]

  • 2. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE, Collaborative Study Group.
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [Abstract] [Full Text] [Related]

  • 3. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [Abstract] [Full Text] [Related]

  • 4. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K, Braunhofer P, Newsome B, Lubeck D, Wang S, Deuson J, Claxton AJ.
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [Abstract] [Full Text] [Related]

  • 5. Factors associated with serum fetuin-A concentrations after long-term use of different phosphate binders in hemodialysis patients.
    Lin HH, Liou HH, Wu MS, Huang CC.
    BMC Nephrol; 2016 Mar 23; 17():33. PubMed ID: 27007989
    [Abstract] [Full Text] [Related]

  • 6. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L, Bernard LM, Elder GJ.
    Clin J Am Soc Nephrol; 2016 Feb 05; 11(2):232-44. PubMed ID: 26668024
    [Abstract] [Full Text] [Related]

  • 7. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA, Galani VJ, Shah PR.
    Saudi J Kidney Dis Transpl; 2014 May 05; 25(3):530-8. PubMed ID: 24821148
    [Abstract] [Full Text] [Related]

  • 8. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.
    St Peter WL, Liu J, Weinhandl E, Fan Q.
    Am J Kidney Dis; 2008 Mar 05; 51(3):445-54. PubMed ID: 18295060
    [Abstract] [Full Text] [Related]

  • 9. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N, Wu X, Ding X, Mei C, Fu P, Jiang G, Li X, Chen J, Liu B, La Y, Hou F, Ni Z, Fu J, Xing C, Yu X, Huang C, Zuo L, Wang L, Hunter J, Dillon M, Plone M, Neylan J.
    Nephrol Dial Transplant; 2014 Jan 05; 29(1):152-60. PubMed ID: 24151017
    [Abstract] [Full Text] [Related]

  • 10. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
    St Peter WL, Wazny LD, Weinhandl ED.
    Am J Kidney Dis; 2018 Feb 05; 71(2):246-253. PubMed ID: 29195858
    [Abstract] [Full Text] [Related]

  • 11. Hyperphosphataemia: treatment options.
    Malberti F.
    Drugs; 2013 May 05; 73(7):673-88. PubMed ID: 23625273
    [Abstract] [Full Text] [Related]

  • 12. Ten-year experience with sevelamer and calcium salts as phosphate binders.
    Raggi P, Vukicevic S, Moysés RM, Wesseling K, Spiegel DM.
    Clin J Am Soc Nephrol; 2010 Jan 05; 5 Suppl 1():S31-40. PubMed ID: 20089501
    [Abstract] [Full Text] [Related]

  • 13. Slowing the progression of vascular calcification in hemodialysis.
    Chertow GM.
    J Am Soc Nephrol; 2003 Sep 05; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
    [Abstract] [Full Text] [Related]

  • 14. The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research.
    Assimon MM, Mousa S, Shaker O, Pai AB.
    Consult Pharm; 2010 Jan 05; 25(1):41-54. PubMed ID: 20211816
    [Abstract] [Full Text] [Related]

  • 15. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Jan 05; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 16. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
    Mohammed I, Hutchison AJ.
    J Ren Care; 2009 Mar 05; 35 Suppl 1():65-70. PubMed ID: 19222734
    [Abstract] [Full Text] [Related]

  • 17. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
    Ahmadi F, Shamekhi F, Lessan-Pezeshki M, Khatami MR.
    Saudi J Kidney Dis Transpl; 2012 Sep 05; 23(5):934-8. PubMed ID: 22982903
    [Abstract] [Full Text] [Related]

  • 18. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
    Nolan CR, Qunibi WY.
    Curr Opin Nephrol Hypertens; 2003 Jul 05; 12(4):373-9. PubMed ID: 12815333
    [Abstract] [Full Text] [Related]

  • 19. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L.
    J Ren Nutr; 2011 May 05; 21(3):277-82. PubMed ID: 20598905
    [Abstract] [Full Text] [Related]

  • 20. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL, Wazny LD, Weinhandl E, Cardone KE, Hudson JQ.
    Drugs; 2017 Jul 05; 77(11):1155-1186. PubMed ID: 28584909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.